Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
2017 · PLoS ONE · 303 citations
https://doi.org/10.1371/journal.pone.0189848
D
David Lorente
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
192
Papers
5.2K
Citations
36
h-index
70
i10-index
David Lorente is an academic researcher from Fundación Instituto Valenciano de Oncología. The author has contributed to research in topics: Prostate Cancer Treatment and Research & Radiopharmaceutical Chemistry and Applications & Cancer, Lipids, and Metabolism. The author has an h-index of 36, co-authored 164 publications.
ORCID: 0000-0001-7550-0657Papers by this author
worksAnalytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer
2016 · European Urology · 124 citations
https://doi.org/10.1016/j.eururo.2016.03.049
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers
2018 · British Journal of Cancer · 107 citations
https://doi.org/10.1038/s41416-018-0082-1
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer
2016 · European Urology · 67 citations
https://doi.org/10.1016/j.eururo.2016.02.055
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
2016 · Clinical Genitourinary Cancer · 40 citations
https://doi.org/10.1016/j.clgc.2016.04.016
Dignity and psychosocial related variables in elderly advanced cancer patients
2022 · BMC Geriatrics · 11 citations
https://doi.org/10.1186/s12877-022-03423-7
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat